Literature DB >> 12780875

Combination treatment in bipolar disorder: a review of controlled trials.

Carlos A Zarate1, Jorge A Quiroz.   

Abstract

OBJECTIVES: Monotherapy is often inadequate and combination drug regimens have become the norm for the treatment of bipolar disorder. Virtually all classes of psychotropic drugs have been used in bipolar disorder in combination for a variety of indications. This article reviews the available published data from controlled, blinded studies regarding combination treatments in the different treatment phases of bipolar disorder.
METHODS: Articles for this review were obtained from a search of the Medline database (1966-2002), using the following keywords and phrases: add-on, antipsychotic, anticonvulsant, antidepressant, combination treatment, lithium, neuroleptic, and polypharmacy. The search was augmented by data presented at scientific meetings. Data included in this article were only from controlled studies that evaluated combinations of two or more agents.
RESULTS: For acute mania, the most useful combination treatments as determined by controlled studies, appear to be an antipsychotic drug with a mood-stabilizer. The combination of lithium and valproate, even though widely used for acute mania, is lacking in controlled data. For acute bipolar depression, the controlled combination studies reviewed fail to show clear advantages in efficacy of an antidepressant with a mood-stabilizer versus two stabilizers or a mood-stabilizer alone. Large, controlled, randomized, long-term studies with modern antidepressants are not available. Controlled combination studies of mood-stabilizers suggest gains in efficacy over monotherapy in the long-term treatment of bipolar disorder.
CONCLUSIONS: Controlled combination studies in bipolar disorder are uncommon. Increased attention should be given to study combination treatments in all phases of bipolar illness to determine the most efficacious and safest combinations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780875     DOI: 10.1034/j.1399-5618.2003.00034.x

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  12 in total

1.  The management of acute mania.

Authors:  Paul E Keck
Journal:  BMJ       Date:  2003-11-01

Review 2.  The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.

Authors:  Hwang-Bin Lee; Bo-Hyun Yoon; Young-Joon Kwon; Young Sup Woo; Jung-Goo Lee; Moon-Doo Kim; Won-Myong Bahk
Journal:  Clin Drug Investig       Date:  2013-10       Impact factor: 2.859

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

Review 4.  Cellular mechanisms underlying affective resiliency: the role of glucocorticoid receptor- and mitochondrially-mediated plasticity.

Authors:  Joshua G Hunsberger; Daniel R Austin; Guang Chen; Husseini K Manji
Journal:  Brain Res       Date:  2009-07-10       Impact factor: 3.252

Review 5.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

6.  High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder.

Authors:  Virginio Salvi; Francesco Barone-Adesi; Virginia D'Ambrosio; Umberto Albert; Giuseppe Maina
Journal:  Psychopharmacology (Berl)       Date:  2015-09-26       Impact factor: 4.530

7.  Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.

Authors:  Yan Leng; Min-Huei Liang; Ming Ren; Zoya Marinova; Peter Leeds; De-Maw Chuang
Journal:  J Neurosci       Date:  2008-03-05       Impact factor: 6.167

8.  Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder.

Authors:  Richard H Weisler; Amir H Kalali; Andrew J Cutler; Thomas D Gazda; Lawrence Ginsberg
Journal:  Psychiatry (Edgmont)       Date:  2008-05

Review 9.  Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders.

Authors:  Daniel Z Lieberman; Frederick K Goodwin
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 8.081

10.  FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers.

Authors:  Y Leng; Z Wang; L-K Tsai; P Leeds; E B Fessler; J Wang; D-M Chuang
Journal:  Mol Psychiatry       Date:  2014-01-28       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.